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Abstract
Background: In Bangladesh, most patients with Guillain-Barré syndrome (GBS) cannot afford standard treatment
with intravenous immunoglobulin (IVIG) or a standard plasma exchange (PE) course, which partly explains the high
rate of mortality and residual disability associated with GBS in this country. Small volume plasma exchange (SVPE) is
an affordable and potentially effective alternative form of plasma exchange. SVPE is the repeated removal of small
volumes of supernatant plasma over several days via sedimentation of patient whole blood. The aim of this study is
to define the clinical feasibility and safety of SVPE in patients with GBS in resource poor settings.
Methods: A total of 20 adult patients with GBS will be enrolled for SVPE at a single center in Bangladesh. Six daily
sessions of whole blood sedimentation and plasma removal will be performed in all patients with GBS with a target
to remove an overall volume of at least 8 liters (L) of plasma over a total of 8 days. Serious adverse events (SAE) are
defined as the number of patients developing severe sepsis associated with the central venous catheter or deep
venous thrombosis in the limb where the catheter is placed for SVPE. Based upon a predictive success rate of 75%,
the SVPE procedure will be considered safe if less than 5 of 20 SVPE-treated GBS patients have a SAE. The
procedure will be considered feasible if 8 L of plasma can be removed in at least 15 of 20 patients with GBS who
receive SVPE. In addition, detailed clinical and neurological outcome assessments will be performed until discharge
of the patient from the hospital and up to 4 weeks after study entry.
Discussion: This is the first clinical study to evaluate the feasibility and safety of SVPE as a potential alternative
low-cost treatment for the patients with GBS in resource poor settings.
Trial registration: Clinicaltrials.gov NCT02780570
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Background
Guillain-Barré syndrome (GBS) is an acute poly-
radiculo-neuropathy with a yearly incidence of 1.2 to 2.3
per 100,000 [1]. GBS is characterized by rapidly progres-
sive symmetrical weakness of the limbs that reaches a
plateau within 4 weeks. Recovery usually starts after a
plateau of 2 to 4 weeks but may be delayed for months
[2]. In addition, some patients experience sensory,
cranial, or autonomic nerve deficits or respiratory fail-
ure. GBS is highly variable with respect to its clinical
and electrophysiological presentation and differs
between patients from the Eastern and Western hemi-
sphere [3–5]. Acute inflammatory demyelinating
polyneuropathy (AIDP) [3, 4] with sensory-motor
involvement is the predominant form in the Western
world whereas most patients in Asian countries have the
acute motor axonal neuropathy (AMAN) form. At
present two treatment interventions are used, that has-
ten the recovery of GBS. Plasma exchange (PE) was the
first treatment proven to be effective in GBS, if given
within 4 weeks of the onset of weakness [2, 3, 6–12].
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Four sessions of standard PE (50 mL/kg plasma per
session) in exchange with fresh frozen plasma (FFP) or
albumin-saline mixture is beneficial in patients with
GBS who are unable to walk at nadir [7, 13–16]. Effi-
cacy of intravenous immunoglobulin (IVIG) (0.4 g/kg
per day for 5 days) is similar to PE if given within
2 weeks of the onset of weakness in patients with GBS
who are unable to walk [17, 18].
In low-income countries, most patients cannot afford
treatment with either PE or IVIG [19]. In Bangladesh, a
full course of IVIG for a 60-kg adult costs approximately
12,000–16,000 USD, and treatment with conventional PE
for 5 days costs approximately 4500–5000 USD. As a re-
sult, only 15% of patients with GBS in Bangladesh are
treated with IVIG or PE, while the remaining 85% of pa-
tients only receive supportive care. Patients with GBS in
Bangladesh have a poor prognosis compared to patients in
Western countries. We previously reported a mortality
rate of 14% and observed 29% of patients with GBS in
Bangladesh are unable to walk 6 months after disease on-
set, which may in part be due to the low rates of specific
treatment with PE or IVIG [5].
Small volume plasma exchange (SVPE) may represent
an effective alternative treatment for GBS. SVPE is based
on the same principle as conventional PE but uses a
novel but simple technique and has a much lower cost
(approximately 500 USD). SVPE is achieved by repeated
removal of small volumes of supernatant plasma over
several days via sedimentation of patient whole blood.
This study was designed to investigate the safety and
feasibility of SVPE in 20 patients with GBS admitted to
the National Institute of Neurosciences and Hospital in
Dhaka, Bangladesh.
Specific objectives
The objective of this study is to determine the safety and
feasibility of SVPE in patients with GBS in Bangladesh.
Methods/design
Study design
In this safety and feasibility study, 20 adult patients with
GBS will be enrolled for SVPE at the National Institute
of Neurosciences and Hospital, Dhaka, Bangladesh. Pa-
tients will be monitored according to a standard proto-
col throughout the course of SVPE until the second day
after withdrawal of the central venous catheter (CVC) to
assess predefined measures of feasibility, safety, and
neurological recovery. To compare the safety of SVPE in
patients with GBS in the context of the background risk
of central line-associated blood stream infection
(CLABSI) at our institution, we will assess the incidence
of CLABSI in a control group of adult patients with a
diagnosis other than GBS admitted to the same intensive
care (ICU) and high-dependency care (HDU) units in
the same period of time (Fig. 1 and Table 1).
Patient recruitment began in March 2016 and is
expected to last for 18 months. Final analysis and prep-
aration of manuscript will be done within 3 months after
the last patient with GBS completes the SVPE.
Ethical consideration
The protocol was reviewed and approved by the Institu-
tional Review Board (IRB) consisted with Research
Review Committee (RRC) and the Ethical Review Com-
mittee (ERC) at icddr,b (Protocol Number: PR-15086,
Version no. 3, Date: December 9, 2015). The study will
be performed according to the Declaration of Helsinki
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for the small volume plasma exchange (SVPE) safety and feasibility study
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[20]. Only patients who provide informed signed consent
to the study physician would be included in the study.
The participants will be informed that participation in
the trial is voluntary and that they can withdraw consent
at any time without giving reasons. Expenditure for the
patients with GBS treated with SVPE and any harm
related to the SVPE will be fully compensated.
Patient enrolment—case definition
Patients with GBS
Patients ≥ 18-years of age fulfilling the diagnostic criteria
for GBS of the National Institute of Neurological and
Communicative Disorders and Stroke (NINDS) [21] will
be enrolled, provided they are unable to walk unaided
for more than 10 meters (GBS disability score ≥ 3),
presented within 2 weeks of the onset of weakness, and
are unable to afford standard treatment with IVIG or
PE. Patients with severe or terminal concomitant illness,
evidence of healthcare-associated infection on admission
(except for aspiration pneumonia), or a previous history
of severe allergic reaction to properly matched blood
products and pregnant women will be excluded from
the study.
Patients without GBS
Patients ≥ 18-years of age with a diagnosis other than
GBS requiring a CVC for > 2 to ≤ 8 calendar days after
admission to the same ICU and HDU units in the same
period of time will be eligible. Patients with healthcare-
associated infection present on admission (except aspir-
ation pneumonia) and pregnant women will be excluded
from the control group.
Primary outcome measures
The primary outcome measures of safety are the number
of patients with GBS treated with SVPE developing severe
sepsis or septic shock (Additional file 1 for standardized
definitions: Appendix 1A) due to CLABSI [22] and the oc-
currence of venous thrombosis in the limb where the
CVC is placed (Additional file 1 for standardized defini-
tions: Appendix 1B). The primary outcome measure of
feasibility is the ability to remove at least 8 L of plasma
over 8 days.
Secondary outcome measures
The secondary outcome measures of safety of SVPE are
the relative risk of CLABSI due to SVPE compared to
CLABSI in control patients without GBS treated using a
CVC, hemodynamic instability during the SVPE proced-
ure (variations in systolic blood pressure greater than
30 mmHg or sudden bradycardia involving a reduction
in heart rate by more than 20 beats per min within
30 min of starting SVPE or an increase in heart rate
above 120 beats per min), and development of anemia
(Hb < 8 g/dL) or serious hemorrhage requiring blood
transfusion.
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) table for the SVPE safety and feasibility study
Study period
Enrolment Allocation Post-allocation Close-out
Entrya 0 Day 1–3 Day 4 Day 5–8 Day 10 Discharge* Day 30*
Time point
Eligibility screen +
Informed consent +
Allocation +
Interventions
SVPE + + +
Non-SVPE + + +
Assessments
SVPE procedureb + + +
Hemodynamicc + + + + + + +
Biochemistryd + ±‡ ±‡ + ±‡ +
Infection screeninge + ±‡ ±‡ + ±‡ + +
Neurologicalf + + + + + +
*For patients treated with SVPE. ‡ Assessed as per indication
aWithin 14 days of onset of muscle weakness
bNumber and duration of each SVPE session and volume of the plasma removed and the replacement fluid infused
cBlood pressure, heart rate, body temperature, and pulse oximetry
dHemoglobin (g/L), coagulation profile, serum level of calcium, magnesium, albumin, renal, and liver function test
eComplete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein, and microbiological investigations to assess CLABSI, CAUTI, and VAP
fGBS disability score and MRC sum score
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The secondary outcome measures of the feasibility of
SVPE are the rate of CVC occlusion during the SVPE pro-
cedure, the healthcare personnel’s acceptability and satis-
faction with the SVPE procedure, and any unanticipated
events compromising the SVPE procedure as assessed
using a standard questionnaire (Additional file 1 for stan-
dardized definitions: Appendix 1C). In addition, neuro-
logical outcome will be assessed in terms of improvement
in GBS disability score [23] and MRC sum score [24] at
discharge and up to 4 weeks after entry.
Attempts to minimize the risks associated with SVPE
All connection ports of the SVPE kit (Fig. 2), the lumens
of the CVC, the blood bag, and the saline bag will be
disinfected with 70% alcohol and then air-dried before
sampling blood or disconnection. Strict aseptic proce-
dures will be followed to prevent CLABSI [25–27]. The
SVPE procedure will not be started or stopped tempor-
arily after the start of SVPE in patients who develop
hypotension (30 mmHg decrease in systolic blood pres-
sure, systolic blood pressure < 90, or MAP < 65 mmHg)
or cardiac arrhythmia for any reason. After correction of
hypotension and/or cardiac arrhythmia, the SVPE pro-
cedure will be started or restarted if SVPE stopped due
to autonomic instability. The CVC will be removed as
soon as SVPE is completed or the CVC will be immedi-
ately relocated to another insertion site if a CLABSI
related to the CVC used for SVPE is confirmed or
strongly suspected. Patients with GBS having severe
sepsis as per standardized definition (Additional file 1:
Appendix 1A) due to any organ site-specific infection
present on admission (except for aspiration pneumonia)
will be excluded for SVPE. Otherwise, any covert infec-
tion or aspiration pneumonia, as may be indicated by
leukocytosis, will be investigated and treated accordingly
after consultation with a medical microbiologist. Normal
hemoglobin concentration for > 18 years man and non-
pregnant woman will be considered as 13 and 12 g/dL,
respectively [28]. However, blood transfusion will be
considered to correct severe anemia (hemoglobin level
< 8 g/dL [28]) before, during, or after SVPE. Proper
screening of FFP for specific infective agents (hepatitis B
and C viruses, human immunodeficiency virus (HIV),
and syphilis) will be performed prior to administration
of FFP.
Documentation (Table 1)
Baseline assessment and re-evaluation
Complete blood counts, including hemoglobin (g/L),
erythrocyte sedimentation rate (ESR), C-reactive protein,
and coagulation profile as well as serum calcium, mag-
nesium, albumin, creatinine, bilirubin, and SGPT will be
documented as baseline assessments for patients with
GBS treated with SVPE, along with screening for hepa-
titis B, C, and HIV. Baseline assessments will be re-
evaluated on day 4 (interim analysis) and day 10 (second
day after completion of SVPE and removal of the CVC)
after initiation of SVPE.
Fig. 2 Illustration of the small volume plasma exchange (SVPE) kit. A SVPE kit will be prepared with one blood transfusion set and two saline
infusion sets connected via a tri-channel device. The blood transfusion set will be connected to the blood bag and a saline infusion set will be
connected to 1 L normal saline mixed with 2500 units of unfractionated heparin and the other ends of the blood transfusion and saline infusion
sets will be connected with one lumen of the central venous catheter using a tri-channel device. Another saline infusion set will be connected to
500 mL hexa-ethyl starch solution and the other end connected with the second lumen of the central venous catheter. Air should be eliminated
from all tubes using fluid from the respective bags
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The procedure, hemodynamic parameters, and cost for SVPE
SVPE will be documented in terms of the duration and
amount of plasma removed in each session, the type and
volume of replacement fluid, and FFP used (Fig. 3).
Throughout the procedure, hemodynamic status includ-
ing blood pressure, heart rate, any cardiac arrhythmia,
oxygen (%) saturation in peripheral blood, and fluid in-
take and output will be monitored daily according to the
protocol. Autonomic parameters especially the presence
of high or low blood pressure, increased or decreased
pulse rate, and cardiac arrhythmia will be monitored and
treated accordingly, before and after each SVPE session
(12 times a day) and if necessary during and in between
the SVPE sessions. Bladder and gastrointestinal dysfunc-
tion, pupillary abnormality, unusual sweating, and hyper-
salivation will also be monitored daily. Any inconvenience
experienced by the patient, nurse, or physician that tem-
porarily or permanently compromise the SVPE sessions
(Additional file 1 for standardized definitions: Appendix
1C). The cost for the SVPE in total 8 days will be approxi-
mately 500 US$ [fresh frozen plasma (24 bags) = 240 US$,
blood bag and saline sets: 40 US$, low molecular weight
heparin: 110 US$, routine investigation: 50 US$, saline: 10
US$, CV catheter: 40 US$ = total 490 US$].
The hospital-acquired infections (HAI) and complications
CLABSI and primary and secondary bloodstream infec-
tions [22], catheter-associated urinary tract infection
(CAUTI) [29], ventilator-associated pneumonia (VAP)
[30], and other HAIs [31, 32] will be stringently docu-
mented in SVPE treated patients with GBS and non-
GBS baseline control patients requiring the CVC in the
ICU/HDU area using predefined criteria. Sepsis and se-
vere sepsis will be documented as per protocol definition
(Additional file 1 for standardized definitions: Appendix
1A). All cases of definite or strongly suspected CLABSI
related to SVPE will be followed up until discharge to
document the severity of CLABSI. Appropriate clinical
data, imaging, and biochemical and microscopic analyses
of specimens and bacteriological cultures will be docu-
mented as per indication of site-specific infections.
Device-associated complications including CVC occlu-
sion, hemorrhage, and deep vein thrombosis [33] will be
documented in real-time.
Fig. 3 SVPE procedure for patients with GBS. A loading dose of low-molecular weight heparin (1.5 mg/kg) will be given subcutaneously at least
2 hours before initiation of SVPE; the same dose will be administered once daily or divided into two equal doses daily for 8 days or until SVPE is
completed. Whole blood (7 mL/kg body weight) will be drawn from the central venous catheter into the blood transfusion bag in each session.
The blood bag will be hung beside the patient for 2.5 h on a saline stand and left uninterrupted to allow plasma and blood cells to separate.
The blood cells will be infused back into the patient and plasma will be discarded and replaced with fresh frozen plasma and colloid solution
alternately (in equal volumes) via the closed-circuit SVPE kit illustrated in Fig. 2. In case of excessive clotting (bleeding time reduction of > 50%
of baseline for that patient), aspirin (600 mg) will be administered orally at least 2 hours before the next SVPE session and continued thereafter
at 150 mg orally/day until SVPE is completed. One blood bag will be used each day, with a total of six sessions/day. A total of 48 sessions will
be performed over 8 days, removing approximately 8000 mL plasma in total
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Neurological function
Neurological examinations will be performed to monitor
the clinical changes in motor, sensory, and autonomic
parameters before and during the procedure and in the
subsequent follow-up of patients lasting up to 4 weeks.
Disability and motor function will be assessed using the
GBS disability score [23] and MRC sum score [24]. Som-
atic and proprioceptive sensation of the limbs will be
assessed bilaterally.
Sample size
This safety and feasibility study will enroll 20 patients
with GBS for SVPE. We cannot perform a formal power
calculation for this safety and feasibility study. The
sample size is based on previous pilot studies in GBS
[34, 35]. The baseline rate of CLABSI will be measured
in parallel in patients without GBS (and not undergoing
SVPE) admitted to the same study facility who require a
CVC during the study period. All control patients avail-
able during the inclusion time period will be included.
We expect to obtain at least 20 or more (i.e., the max-
imum number of patients possible during the study
period) control patients without GBS who require a
CVC for at least 2 days and maximum of 8 days.
Indication to stop the trial
Decision to stop the SVPE trial will be designated as per
a Bayesian approach [36–38]. Accordingly, a predictive
success rate of 75% will be set for the SVPE procedure.
If more than 5 of 20 patients experience an SAE or when
it appears to be impossible to remove at least 8 L of
plasma in at least 15 individual patients, the procedure
will be considered unsafe or unfeasible, respectively.
Data management
The unique patient identity (ID), name, date of birth,
and basic demographic and clinical data of the SVPE-
treated patients and control patients will be stored sep-
arately in paper and electronic database documentation
and updated on a daily basis. All the privacy-sensitive
data will be stored encrypted. In case of withdrawal,
follow-up and data collection will continue with the par-
ticipant’s permission. A data safety monitoring board
(DSMB) consisting of clinical experts, a microbiologist,
and a biostatistician from the icddr,b ERC committee
will be responsible for the monitoring and review of the
safety and conduct of this safety and feasibility study.
The DSMB will function independently and has the right
to audit the study without notice to the investigators
and the sponsor. Important protocol amendments for
approval and AEs that occur at a greater frequency or
intensity than expected will be reported to the IRB of
the icddr,b within 7 business days. However, any AE
without any discretion will be reported to the DSMB
and the ERC within 24 h. Upon completion of the trial,
all study-related data and trial documents will be ar-
chived securely at the icddr,b and retained for a mini-
mum of 10 years. The corresponding author will have
full access to all the data in the study and will be respon-
sible for the decision to submit the publication.
Statistical analysis
The rate of HAIs (CLABSI, CAUTI, VAP) per 1000 device
days will be calculated by dividing the number of HAIs
(CLABSI, CAUTI, VAP) during the study period by the
number of device days and multiplying the result by 1000.
The infection safety profile for SVPE will be assessed by
calculating the standardized infection ratio (SIR) to define
the risk of HAI in patients with GBS treated with SVPE.
The SIR will be calculated by dividing the number of ob-
served infections by the number of infections predicted
(i.e., the infection rate in the control group). The predicted
HAI rate will be calculated using the rates of HAI in the
control group of patients without GBS during the study
period. Percentage values will be compared using chi-
square test or Fisher’s exact test (two-tailed) and median
values, the Mann-Whitney U test using SPSS 22 software
(IBM Corp. Released 2013. IBM SPSS Statistics for Win-
dows, Version 22.0. Armonk, NY: IBM Corp). Analyses will
be performed on an intention-to-treat basis. All p values
reported will be two sided, and a difference of p < 0.05 will
be considered significant.
Discussion
SVPE is based on the removal of supernatant plasma
after sedimentation of whole blood and represents a pu-
tative alternative treatment for GBS in low-income
countries where most patients cannot afford PE or IVIG
[19]. In countries like Bangladesh, a safe, effective treat-
ment needs to be available at local hospitals so patients
can obtain medical care as soon as possible. Considering
the current infrastructure and high costs of specific
treatments, access to IVIG or standard PE remains a
challenge for many patients with GBS in Bangladesh and
other low-resource developing countries.
Compared to conventional PE (four sessions at a rate of
50 mL/kg plasma removal per session [7, 13–16]; approxi-
mate removal of 12 L of patient plasma in total), a slightly
lower volume of plasma is exchanged during SVPE, though
this volume is reached by daily exchange of small volumes
of plasma (approximately 1 L/day). The potential advan-
tages of SVPE are its simplicity and low cost (approxi-
mately 500 USD) and the fact that it does not require
advanced equipment and can be performed over 8 days
compared to standard PE, which requires a total period of
10 to 14 days. Before assessing the potential efficacy of
SVPE for GBS, it is essential to define the feasibility and
safety of this therapeutic intervention in local hospitals.
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SVPE is time-consuming, and the ability to complete
uninterrupted treatment could be hampered due to
autonomic dysfunction. Considering these issues, we
predefined the criterion that SVPE will be considered
feasible if at least 8 L of plasma can safely be removed in
8 days. Infections related to the CVC are the major
safety concern during SVPE. The rate of HAI may be
much higher in low-income countries, especially in the
Southeast Asia, compared to high-income countries.
According to the International Nosocomial Infection
Control Consortium (INICC), the rates of CLABSI are
significantly higher in ICUs in low-income countries (6.8
per 1000 central line-days) than the US (2.0 per 1000
central line-days) [39]. Additionally, the microbiologic
spectrum varies, with a higher tendency for gram-
negative bacteria to cause CLABSI in developing coun-
tries [40–43] as opposed to gram-positive bacteria in
developed countries [27]. Poor infrastructure, inadequate
hygienic maneuvering of vascular catheters, and a lack
of knowledge regarding CVC safety may contribute to
the increased risk of CLABSI in developing countries.
Additionally, the indiscriminate use of broad-spectrum
antibiotics further escalates multi-drug resistance.
No data is available on the prevalence of CLABSI within
ICUs or HDUs in Bangladesh. Therefore, this study will
systematically document the rate of CLABSI in the ICU/
HDU of the institution, at which this study is being con-
ducted, with the aim of comparing the baseline risk of
infection with the risk of CLABSI associated with SVPE.
Implementation of the protocol-defined safe techniques
for vascular catheter handling and maintenance could
improve the knowledge and awareness of the health
personnel at the study facility. Eventually, a positive
impact on safety is expected in terms of infection control.
Though SVPE is a simple procedure, the motivation of
and coordination between doctors and nurses is critical to
the feasibility of this technique. Therefore, we decided to
employ a questionnaire-based qualitative approach to as-
sess the experiences of the participating medical personnel
with the SVPE procedure. However, a drawback is the fact
that we did not assess psychometric properties of this
questionnaire in the study settings. However, our consid-
eration is to generate some evidence within the study.
Continuous wide-lumen tubing with built-in keys to
direct blood/saline flow reduces manipulation and may
reduce the chance of contamination. However, these sys-
tems are currently unavailable in Bangladesh; therefore,
we employed multiple thin-lumen tubing systems inter-
connected with a multichannel connecter device.
Important advantages of SVPE over standard PE are
the low cost and ability to perform SVPE by the bedside
of the patient. In most hospitals in Bangladesh, patients
requiring mechanical ventilation cannot be transferred
to the PE facility, as there is no facility for mobile PE.
Moreover, SVPE could represent a therapeutic option in
resource-limited settings that lack the facility for PE.
Should the SVPE procedure be feasible and safe, we plan
to conduct a randomized control trial in the future to
determine the clinical efficacy of SVPE for the treatment
of GBS in developing countries as an alternative to con-
ventional treatment with IVIG or PE.
Recruitment status
Recruitment has been completed with 20 cases of GBS
treated with SVPE and 24 control cases without GBS in
June 2017.
Additional file
Additional file 1: Standardized definitions. (DOCX 85 kb)
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